Basic fibroblast growth factor or fibroblast growth factor-2 (FGF) has been shown to affect myeloid cell proliferation and hypothesized to stimulate primitive hematopoietic Cells. We sought to evaluate the effect of FGF on hematopoietic stem cells and to determine if FGF mediated its effects on progenitor cells directly or through the induction of other cytokines. To address the direct effects of FGF, we investigated whether FGF induced production of interleukin-l/3 (IL-IB), tumor necrosis factor a, IL-6, granulocyte colony-stimulating factor, or granulocyte-macrophage colony-stimulating factor by two types of accessory cells, bone marrow (BM) fibroblasts and macrophages. We further evaluated whether antibodies to FGF-induced cytokines affected colony formation. To determine if FGF was capable of stimulating multipotent progenitors, we assessed the output of different colony typea after stimulation of BM mononuclear cells (BMMC) or CD34+ 6°C
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and compared the effects of FGF with the stem cell active cytokine, kit ligand (KL). In addition,
ASIC FIBROBLAST GROWTH factor (FGF) affects
the proliferation and function of a wide range of primary tissues, including blood-forming elements.'" The effects of FGF on hematopoiesis have been previously described and include enhancement of myeloid cell numbers as reflected by increases in granulocyte and granulocytemacrophage colonies (colony-forming unit-granulocyte [CFU-G] and colony-forming unit-granulocyte-macrophage [CFU-GM]), increases in burst-forming units-erythroid (BFU-E), and enhanced megakaryocyte ~roliferation.~.~ FGF has also been noted to alter the activity of primitive human hematopoietic progenitors" augmenting the effects of other cytokines on granulocytehonocyte, erythroid, or mixed lineage colony formation and to increase spleen colony-forming units (CFU-S) from mice.7 However, the studies to date indicate that there is little effect on hematopoiesis by FGF alone; rather, this cytokine enhances the activity of other growth factors on precursor cells. A similar potentiating function has been noted for the kit ligand (JSL), which acts synergistically with FGF in enhancing colony formation."
The goals of this study were to further define the mechanisms of FGF's effects on hematopoiesis, specifically addressing three questions: (1) does FGF mediate its activity directly or through the altered production of other cytokines by accessory cells, ( 2 ) what is the effect of FGF relative to KL on hematopoietic cells, and (3) is FGF capable of stimulating the most primitive blood progenitors or only those committed to the myeloid lineage of differentiation? To address the first question, we assessed the production of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-l@ (IL-l@), tumor necrosis factor a (TNFa), and IL-6 by purified populations of human primary bone marrow (BM) stromal fibroblasts and peripheral blood (PB) monocyte/macrophages in response to FGF. To address the second question, the relative activity of FGF and KL on BM mononuclear cells (BMMC) was measured in standard colonyforming assays. The issue of activity of FGF on primitive progenitors was evaluated using a functional stem cell en-
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Blood, Vol 86, No 6 (September 15). 1995: pp 2123-2129 a subset of CD34+ BMMC with characteristics of hematopoietic stem cells was isolated by functional selection and their response to FGF was evaluated using proliferation, colonyforming, and single-cell polymerase chain reaction (PCR) assays. We determined that FGF had a stimulatory effect on the production of a single cytokine, 11-6, but that the effects of FGF on colony formation were not attributable to that induction. FGF was more restricted in its in vitro effects on BM progenitors than KL was, having no effect on erythroid colony formation. FGF did not stimulate stem cells and FGF receptors were not detected on stem cells as evaluated by single-cell reverse transcription PCR. In contrast, FGF receptor gene expression was detected in myeloid progenitor populations. These data support a directly mediated effect for FGF that appears to be restricted to lineage-committed myeloid progenitor cells. FGF does not appear to modulate the human hematopoietic stem cell. 0 1995 b y The American Society of Hematology.
richment strategy developed in our laboratory,I2 determining the expression of FGF receptors by single-cell reverse transcription-polymerase chain reaction (RT-PCR) as well as measuring the biologic response to FGF and other cytokines using proliferation assays.
MATERIALS AND METHODS

Cells
BM stromal cell culture. Human BM was obtained by aspiration from the iliac crest of normal donors who provided voluntary written informed consent to a Deaconess Hospital Institution Review Board approved protocol. The marrow was aspirated into preservative-free heparin (Sigma, St Louis, MO) and separated by centrifugation through Ficoll-Hypaque (Pharmacia, Piscataway, NJ) at 400g at room temperature for 30 minutes. After two washes with sterile 1 X Iscove's modified Dulbecco's media (IMDM; GlBCO, Grand Island, NY) with 20% fetal calf serum (FCS; Hyclone, Logan, UT), penicillin/streptomycin (P/S), and L-glutamine, the cells were seeded onto T-75 tissue culture flasks (Coming, Coming, NY) and incubated at 37°C in 5% COz. After 48 hours, the nonadherent cells were gently removed and the adherent cells were refed with fresh medium. The cells were refed with fresh medium every 3 days and trypsinized and split after 1 week or when confluent. Cells underwent three cycles of trypsinization and splitting to exclude macrophage contamination, as previously reported."
Macrophage isolation. PB mononuclear cells (PBMC) were iso-
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BERARDI ET AL lated from heparinized blood samples using Ficoll-Hypaque (Pharmacia) at 400g at room temperature for 30 minutes. After two washes with RPM1 with 10% FCS, P/S, and L-glutamine, the cells were incubated in a tissue culture dish (Falcon Plastics, Cockeysville, MD) at 37°C in 5% CO, for monocyte (MO) separation. After 4 hours, the nonadherent cells were gently removed and the adherent cells were refed with fresh medium containing 10 U/mL recombinant human macrophage colony-stimulating factor (M-CSF; gift of Genetics Institute, Cambridge, MA). The cultures were refed with fresh medium plus M-CSF every 3 days. In previous studies, greater than 95% of the resultant cells stained positively with a monoclonal anti-M02 (CD14) antibody by flow cytometric analy~is.'~ For cytokine stimulation assays, macrophage or fibroblast cultures were washed and refed with serum-free, endotoxin-free medium supplemented with cytokines or lipopolysaccharide (LPS; Sigma) as noted.
Isolation of CD34' enriched BM. BM was obtained as described above. The cells were layered on Ficoll-Paque (1.077 g/mL; Pharmacia) and centrifuged at 850g at 22°C for 20 minutes. The lowdensity BMMC were collected from the interface, washed twice with phosphate-buffered saline (PBS), resuspended in IMDM containing 15% FCS, and plated in 75-cm2 flasks (1 to 2 X lo7 cells in 10 mL).
After an overnight incubation at 37°C and 5% CO2 in a humidified cell culture incubator, the nonadherent cells were recovered. To select for the CD34' phenotype, these nonadherent BMMC were incubated with an anti-CD34 monoclonal antibody (Amac, Inc, Westbrook, ME) at 4°C for 30 minutes, washed, and mixed with magnetic microspheres coated with antimouse IgG (Dynal Inc, Great Neck, NY) at a 0.5 to 1 bead per cell ratio. Rosetted cells were recovered using magnetic separation and then washed three times with IMDM.
CD34' G, phase cell enrichment.
CD34' enriched BMMC (2 x 10' cells/mL) were incubated at 37°C in 5% CO, for 7 days with 2.0 mg/mL 5-fluorouracil (5-FU; Solo Pack, Elk Grove Village, L)
in IMDM medium supplemented with 10% FCS, KL (stem cell factor [SCF]; 100 ng/mL; R & D Systems, Minneapolis, MN), and L-3 (100 ng/mL; Genzyme). The cell population that survived 5-FU treatment was used in this study after three washes in IMDM.
Cell Proliferation Assays
Cells obtained by the above methods were washed twice with PBS, counted, and distributed into 96-well plates in IMDM containing 10% FCS supplemented with cytokines as indicated: FGF (10 ng/mL; Scios Nova, Mountain View, CA), leukemia inhibitory factor (LIF; 10 ng/mL), IL-lp (400 pg/mL), IL-6 (50 ng/mL), IL-11 (10 ng/mL), SCF (10 ng/mL), or PIXY (10 ng/mL; R & D Systems). The cells were incubated at 37°C in 5% CO, with twice weekly refeeding using growth medium supplemented with cytokines. After 3 weeks, the cells were counted and viability was determined by Trypan blue exclusion and transferred into methylcellulose-containing medium for colony-forming assays.
Methylcellulose Colony Formation Assays
Adherence-depleted low-density BMMC (5 X 104/mL), CD34'-enriched BMMC (4 X 103/mL), or cytokine-stimulated G, cells were suspended in 10 X 35 mm gridded culture dishes with 0.9% methylcellulose (Stem Cell Technology, Inc, Vancouver, British Columbia, Canada), 30% FCS, lo-' m o m 2-mercaptoethanol, 2 mmoVL Lglutamine, 2 U/mL recombinant human erythropoietin, and 10 ng/ mL GM-CSF. KL, FGF, or specified antibodies were added for specific experiments as indicated. The cells were plated in triplicate, incubated in a 5% CO, environment at 37°C for 14 days, and scored by phase microscopic morphology for multilineage colonies (colonyforming unit-granulocyte, erythrocyte, megakaryocyte, macrophage [CFU-GEMM]), BFU-E, or granulocyte-macrophage colonies -(CFU-GM). The range of control colony production for different donor marrows was as follows: for CFU-GM, 28 to 68 colonies/ assay from BMMC and 67 to 182 colonies/assay from CD34' cells; for BFU-E, 18 to 25 burstdassay from BMMC and 28 to 52 bursts/ assay from CD34+ cells.
Single-cell PCR
Using a Becton Dickinson Cell Deposition Unit instrument (Becton Dickinson, Fullerton, CA), single cells were plated in a 96-well plate directly into 4 pL lysis buffer [50 mmoVL Tris-HCI, pH 8.3; 75 mmoVL KCI; 3 mmoVL MgCI,; 2 pmoVL of each deoxyribonucleotide triphosphate (Pharmacia); 100 ng/mL (dT)24; 100 U/mL Inhibit Ace (5'-3' Inc, Boulder, CO), 2,000 U/mL RNAguard (Pharmacia), and 0.5% NP-401 as previously described by Brady et al. '5 The samples were heated to 65°C for 1 minute, cooled to 22°C for 3 minutes, and put on ice. The resultant lysate was then subjected to reverse transcription and PCR.
One hundred units of Moloney (GIBCO-BRL) and 2 U of avian reverse transcriptase (Pmmega, Madison, WI) were added and the samples were incubated at 37°C for 15 minutes. The reverse transcriptases were thereafter inactivated at 65°C for 10 minutes. Cellfree and reverse transcriptase-free samples were used as negative controls. Poly(A) tailing of the single-cell cDNA was performed in 200 mmoVL potassium cacodylate, 4 mmoVL CoCI,, 0.4 mmoVL dithiothreitol (DTT), and 10 U of terminal transferase (Bcehringer Mannheim, Indianapolis, IN). After the addition of 200 pmoVL dATP, the samples were incubated at 37°C for 30 minutes. After heat-inactivation of the enzyme, the cDNA was either amplified immediately or stored at -80°C until use.
The tailed cDNA was added to a PCR buffer containing l 0 mmoll L Tris-HCI, pH 8.3, 50 mmoVL KCl, 2.5 mmoVL MgCl,, 1 mmoll L each of dNTP 0.05% Triton X-100, 5 pmoVL (dTL4 X primer, and 5 U of Taq polymerase (Perkin-Elmer Cetus, Newton Centre, MA). The sequence of the PCR primer (dT)% X was ATG TCG TCC AGG CCG CTC TGG ACA AAA TAT GAA TTC dT(24). Amplification was performed for 25 cycles (1 minute at 94"C, 2 minutes at 42"C, and 6 minutes at 72°C plus 10 seconds of extension per cycle). Thereafter, an additional 5 U of Taq polymerase was added, followed by another 25 cycles of amplification. After electrophoresis and transfer to a nylon membrane, the resultant blots were hybridized with "P-radiolabeled probes from cytokine receptor cDNAs, including extreme 3' sequences.
Oligonucleotide probes from the cDNA sequence of human the human FGFR-2 (AGGCAGCACAGCAGACTAGTTAATCTA-TTGCTTG), human FGFR-3 (TCGACC7TGAGCAGCCCTCCC-TGCTGCTGGTGCA), or human FGFR-4 (GCCTGCCGAAAACAGGAGCAAATGGCGmATA) were also radiolabeled and used as probes."-*' cDNA probes were labeled with [a-3*P1-dCTP (DuPont NEN Research Products, Boston, MA) using random primed DNA labeling (Stratagene, La Jolla, CA). Oligonucleotide probes were end-labeled using [y-7'P]-ATP (DuPont NEN Research Products) and T, polynucleotide kinase (New England Biolabs, Beverly, MA). After prehybridization, the membranes were hybridized (SO% formamide, 6 x SSPE, SX Denhardt's solution, 0.2% sodium dodecyl sulfate [SDS] , and SO pg/mL denatured ssDNA for cDNA probes, or 20% formamide, 6X SSPE, 2X Denhardt's solution, and 1 0 0 yg/mL ssDNA for oligonucleotide probes) at 42°C for 16 to 18 hours. The membranes were washed with medium stringency ( I X for IS minutes with 5X SSC, 0.58 SDS at room temperature, 2 x for IS minutes with 1 X SSC, 0.5% SDS at 37°C and 2 minutes with 0 . 2~ FGFR-I (ACACGCCCTCCCCAGACTCCACCGTCAGCTGTAA), SSC, 0.5% SDS at 40°C) and exposed to x-ray film at -80°C for 4 hours to I week.
RESULTS
Cytokine Stimulation Assays
Monocyte/macrophage or BM stromal fibroblast preparations were generated and exposed to endotoxin-free, serumfree medium containing FGF at concentrations of 0, I , IO, or 1 0 0 ng/mL or LPS at 20 ng/mL for 24 hours before harvesting conditioned media for cytokine analysis. Although LPS induced generally robust cytokine responses in macrophage cultures, only IL-6 was increased above baseline after FGF stimulation ( Table 1) . Stromal fibroblasts produced minimal amounts of these cytokines in the supernatant (as has been reported by others),2s.2h except IL-6, which increased approximately threefold in the setting of FGF stimulation. These data are consistent with the conclusion that FGF does not induce a broad range of cytokine output by accessory cells. Rather, FGF effects appear to be relatively restricted and, among the cytokines tested. limited to increases in IL-6.
Relative Eflect of FGF Versus KL on Colon>l Formation by Hematopoietic Progenitor Cells
Low-density, adherence-depleted BMMC were plated in standard methylcellulose colony assays in the presence of FGF alone, GM-CSF, and erythropoietin (Epo) or combinations of FGF and GM-CSF + Epo. FGF induced no colony formation when used by itself, but enhanced the CFU-GM by 35% f 7% ( P < .OS) and 78% f 16% ( P < .OS) when used at 1 .and 10 ng/mL, respectively, in conjunction with GM-CSF and Epo (Fig 1) . These increases were similar in magnitude to what was observed with IO ng/mL KL (64% t 21 %). However, unlike KL, there was no enhancement in the production of BFU-E with FGF. Colony size was approximately equivalent when evaluating CFU-GM or CFU-mix in the presence of FGF or KL, whereas BFU-E size was increased by KL alone.
Similar effects were noted when using CD34' cells. The CFU-GM increased 35% t 10% ( P < .OS) and 54% t 13% ( P < .OS) when FGF at 1 and IO ng/mL, respectively, was added to cultures containing GM-CSF and Epo (Fig I) . Neither BFU-E nor CFU-mix was affected by FGF. BFU-E were dramatically increased (3.2-fold) by KL treatment.
To assess whether FGF mediated its effect on colony formation via induction of IL-6, we used neutralizing antibodies to IL-6 (R & D Systems) and to FGF (kind gift of Dr Michael Klagsbrun, Children's Hospital, Harvard Medical School, Boston, MA) in methylcellulose assays (Fig 2) . The enhancement of formation of CFU-GM was unaffected by the presence of antibody to IL-6 but was reduced to baseline by anti-FGF antibody. These results were consistent when either BMMC or the CD34' population was evaluated.
effect of FGF on Hematopoietic Stem Cells
Quiescent BMMC with high long-term culture-initiating cell (LTC-IC) ability were isolated and analyzed for both a proliferative and differentiative (as reflected by the acquisition of methylcellulose colony-forming capacity) response to FGF alone or in combination with other cytokines. Cytokine combinations were compared with a stromal feeder layer that is capable of inducing cobblestone formation and CFC detectable by week 3.'' Because of the difficulty in accurately quantitating cell number in the cocultivation system, we qualitatively scored cell or colony numbers using the stroma cocultivation assay as an arbitrary "+ + +" standard. Table 2 indicates the lack of proliferative or differentia- 
Expression sf FGF Receptors on Hematopoietic Stem Cells
Single cells isolated using the Becton Dickinson Cell Deposition Unit (which has a plating accuracy of 0.1%) were used to generate cDNA, as previously described.".'" The cells used were quiescent, functionally selected CD34' cells (G, cells) or cells selected by the immunophenotype shown (Fig 3) derived from either human BM or PB. Five cells of each representative type were used to minimize the likelihood of a single contaminating cell providing misleading information. The resultant cDNAs were ethidium bromidestained and photographed and, after Southern transfer, blotted for the presence of FGF receptor or other cytokine receptor mRNA transcripts. Oligonucleotides derived from the 3' untranslated region of the FGFrI Vg), FGFr2 (hek). FGFr3, or FGFr4 cDNA sequences were used as radiolabeled probes. These FGF receptor probes were compared with stage specific receptors such as the Epo (Epor) or thrombopoietin (cmpl) receptors or more ubiquitously expressed receptors such as the gp130 subunit of the IL-6, IL-I I , LIF, and ciliary neurotropic factor (CTNF) receptors.
The receptor known to be specifically expressed at a later stage, Epor, was restricted in its detection of message to
For personal use only. on November 11, 2017. by guest www.bloodjournal.org From cells of erythroid commitment, as previously reported (data not shown).12 In contrast, gp130, thought to be expressed on a wide range of hematopoietic cells, including stem cells, was detectable (data not shown) in cells representing stem cells, primitive progenitors (CD34+, CD33-), primitive myeloid progenitors (CD34+, CD33+), mature monocyte/macrophages (CD1 lb+), mature T cells (CD3+), and mature B cells (CD19+). Having confirmed the relative specificity of the detection process, we probed with the oligonucleotide probes specific for each of the four FGFr (Fig 3) . Message was detected in mature CDllb' cells and more immature CD34+, CD33+ and most CD34+, CD33-progenitor cells. Although G, cells are CD34+, CD33-, they represent a small subset of those cells because they are approximately 0.1% of CD34+ BMMC, whereas CD33-cells represent approximately 10% of CD34+ cells. The disparate expression data are therefore not inconsistent and support the conclusion that FGF does not affect quiescent, multipotent hematopoietic precursor cells with in vitro characteristics of stem cells. In contrast, kit message was detected in a range of primitive cells including the quiescent, LTC-IC-rich G, fraction, as previously reported (data not shown)." DISCUSSION FGF is a cytokine with pleiotropic effects including effects on multiple cell types comprising hematopoietic tissue. It is known to induce proliferative effects on BM stromal cells as well as altering the growth, adhesion, and cytokine production properties of blood elements. Whereas FGF has been noted to affect myeloid colony production, it has not been determined whether FGF generates these effects directly or via alterations in accessory cells. Neither has it been defined whether FGF exerts effects on the most primitive hematopoietic stem cells.
The studies reported here lead to the conclusion that FGF induces an alteration in production of a single cytokine, IL-6, by macrophages and BM fibroblasts. Other cytokines were unaffected and inhibition of IL-6 by neutralizing antibody had no impact on the hematopoietic effects seen with FGF. Coupled with the data demonstrating message for FGF receptors in myeloid precursors, these data suggest that FGF directly mediates its activity on myeloid progenitor cells.
The data comparing KL with FGF suggest that, although the effects on CFU-GM are similar, there is a dissimilarity in effects on the erythroid lineage. FGF, which is known to also have activity on megakaryocytic cells, would appear to be more lineage restricted in its effects than is KL. Unlike KL, which augments proliferation of all descendants of the myeloid lineage, FGF does not alter erythroid colony number or size. These data imply that FGF may not affect hematopoietic stem cells, as has been previously suggested.'."' Assessing the role of FGF on primitive hematopoietic cells has been problematic due to the difficulty of isolating these cells. The stem cell isolation procedure we developed is based on the observation that cells acquire responsiveness to growth factors in an orderly fashion as they proceed through the process of hematopoietic differentiation. This growth factor responsiveness is manifest as a proliferative response that enhances the sensitivity of the cells to antimetabolite treatment. We have exploited this phenomenon to drive those CD34' cells that respond to the early acting growth factors IL-3 and KL to cell death. The remaining viable cells are immunophenotypically CD34', CD33~~. CD38-, HLA-DR-, and c-kit' with a high capacity for LTC-IC (76% 2 S%) and the ability to form both lymphoid and myeloid progeny." These features support, although they do not conclusively prove, the stem cell nature of the resultant cell population.
We used the cells isolated by this procedure to evaluate functionally and molecularly the role of FGF on stem cells. When these cells are cocultivated with stroma they acquire the ability to generate CFC after an incubation of approximately 3 weeks. In liquid culture, FGF was unable to induce either proliferation or the CFC-producing phenotype in these cells. This lack of effect was observed whether FGF was used alone or in combination with other early acting hematopoietic growth factors. Further, the receptor cDNAs for the four known FGF receptors could not be detected in the qualitative PCR-based system. We would therefore conclude that, although FGF can modulate cells already committed to specific stages of myeloid differentiation, it has no apparent role in regulating the biology of the hematopoietic stem cell.
